iRhythm's Q2 Shock: 20%-Plus Growth Meets 19% Profit Margins

iRhythm's Q2 looks more balanced than a typical growth-stock story

iRhythm is increasingly hard to frame as a growth-only stock.

Earlier this month, the quarter made that clear. Q2 revenue reached $224.2 million and grew 20.1% year over year, while adjusted EBITDA margin reached 19.3%. GAAP net loss also narrowed to $0.01 per share. Those results point to a business that is still growing fast while becoming more efficient at scale.

This quarter also came with new catalysts. iRhythm agreed to acquire VitalConnect, broadening its reach beyond ambulatory ECG, and it received FDA clearance for the third-generation algorithm. That algorithm is expected to cut review time and reduce processing costs over time, which could support margins as volume grows. The main debate is no longer whether iRhythm can grow; it is whether these profits can hold up.

Bulls can point to the mix of high growth, strong margins, and operating leverage in one report. Bears can point to the outstanding FDA warning letter and the execution risk tied to the VitalConnect deal. That is the tension shaping the stock now.

Gross margin and workflow gains are the operating lever

The key question is simple: can each additional case leave more cash behind?

In Q2, the answer looked better than the headline growth rate alone. Gross profit reached $163.2 million, up 22.8% year over year, while gross margin climbed to 72.8%, a 160 basis point improvement. When revenue growth and gross margin expand together, it usually means the business is not just selling more; it is retaining a larger share of every dollar after variable costs.

Why margins can keep widening

This is basic scale economics. If revenue keeps growing while fixed costs stay contained, a larger share of sales can flow through to profit. iRhythm also reported operating expenses: $145M (flat YoY). If that discipline holds while volumes rise, margin expansion has a clearer path.

The newest catalyst in that process is speed. iRhythm said the FDA cleared its third-generation algorithm, which is expected to reduce clinical technician review time by up to 50% and generate about $100 million in cumulative cost savings over five years. In practical terms, faster review should let the company handle more volume without needing a proportionally larger review team.

VitalConnect expands the platform, but execution matters

The VitalConnect deal matters because it takes iRhythm beyond its core ambulatory ECG business. iRhythm agreed to acquire VitalConnect for $287.5 million, and the company said the move expands its portfolio into the full MCT market and adds capabilities in hospital monitoring, hospital-to-home programs, and multivital monitoring.

That broadens the customer base and adds use cases, but it also raises the execution bar. Integration risk is real, and management will need to commercialize the expanded portfolio cleanly if the deal is going to improve margins rather than just expand revenue opportunities.